Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands
Background: Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR). Randomised clinical trials showed a benefit in progression free survival for gefitinib versus doublet chemotherapy regimens in patients with an activated EGFR mutation (EGFR M+). From a patient perspective, progression free survival is important, but so is health-related quality of life. Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus... Mehr ...
Verfasser: |
Verduyn, S. Cora
Biesma, Bonne
Schramel, Franz M. N. H.
van der Scheer, Feike W.
Langenfeld, Merel K.
de Peuter, Maria A.
Dingemans, Anne-Marie C. |
Dokumenttyp: |
Artikel |
Erscheinungsdatum: |
2012 |
Reihe/Periodikum: |
Verduyn , S C , Biesma , B , Schramel , F M N H , van der Scheer , F W , Langenfeld , M K , de Peuter , M A & Dingemans , A-M C 2012 , ' Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands ' , Health and Quality of Life Outcomes , vol. 10 , pp. 108 . https://doi.org/10.1186/1477-7525-10-108 |
Schlagwörter: |
Advanced non-small cell lung cancer
/ Tyrosine kinase inhibitors
/ EGFR mutation
/ Gefitinib
/ Quality of life
/ Progression free survival |
Sprache: |
Englisch |
Permalink: |
https://search.fid-benelux.de/Record/base-26821845 |
Datenquelle: |
BASE;
Originalkatalog |
Powered By: |
BASE |
Link(s) :
|
https://cris.maastrichtuniversity.nl/en/publications/9f8015e8-9a7c-4af0-aa8e-2b4b454c0f2a |